• Medicenna Therapeutics presented Phase 1/2 ABILITY-1 results for MDNA11 in treatment-resistant gastrointestinal cancers at the SITC 2026 Annual Meeting.
• MDNA11 alone or with pembrolizumab produced durable tumor responses, including in patients whose disease had progressed on prior immunotherapy.
• Single-agent treatment reduced all measured liver target lesions in evaluable patients with liver metastases.
• Safety remained manageable, with mostly mild or moderate treatment-related adverse events; adding pembrolizumab produced no new safety signals.
• Additional melanoma and endometrial cancer cohort results will be presented November 10, 2026, expanding evidence for potential registrational studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicenna Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090700PRIMZONECNPR____9873188) on November 09, 2026, and is solely responsible for the information contained therein.